Elekta unveils innovative solutions in precision radiation therapy

As the seventh China International Import Expo unfolds in Shanghai, it serves as a vibrant platform for numerous medical giants to showcase their latest innovations. Among these, global medical equipment provider Elekta stands out as a key player in the field of precision cancer treatment.

At this year's expo, Elekta is unveiling its cutting-edge solutions, emphasizing its vital role in advancing cancer care and reflecting a broader trend toward personalized and precise medical technologies.

Founded in 1972, Elekta has established itself as a leader in the development of advanced technology for cancer treatment. Over the decades, the company has experienced remarkable growth, expanded its footprint across various continents and enhanced product offerings.

Today, Elekta serves more than 7,000 medical institutions in more than 120 countries, benefiting more than 2 million patients annually.

"We have launched several innovations in the past few years and we are now bringing online adaptive technology across all our solutions to increase value and patient outcomes," said Gustaf Salford, president and CEO of Elekta.

As the second-largest medical market globally, China has become a focal point in Elekta's growth strategy, driven by the urgent demand for effective cancer treatment options.

Since entering the Chinese market in 1982, Elekta has adhered to the principle of "In China, For China".This philosophy has guided the company in introducing high-standard international precision radiotherapy solutions and professional services while increasing its investment in the region to foster high-quality innovation.

"In China, we have research and development teams in Shanghai and also in Beijing, developing for the Chinese market but also for the global markets," said Salford. He expressed optimism about the company's prospects, citing the nation's favorable business climate and promising healthcare industry.

Elekta has launched two strategic joint ventures: one with Sinopharm's China National Pharmaceutical Foreign Trade Corporation in 2023 and another with Beijing Ansheng, a leader in local medical informatics in 2024. These collaborations are designed to enhance the quality of radiation therapy while expanding the accessibility of Elekta's advanced solutions throughout China.

"We recognize that China is a significant driving force in global healthcare development, and we are proud of having operated here for more than 40 years. With the Chinese commitment to enhance cancer care, we believe this will continue to be a high-quality business environment for us, which will foster innovation in life science," Salford said.

Continuing its tradition of debuting innovative products at the CIIE, Elekta this year is showcasing a full range of precision radiation therapy solutions, including intelligent adaptive radiotherapy platforms and the world's first MRI real-time adaptive radiotherapy solution.

One of the exhibits unveiled at the CIIE is the Asia debut of Elekta's latest product, a comprehensive solution that provides clinicians with the flexibility to treat every patient and indication. This new product features AI-powered high-definition imaging and efficient workflow automation to offer both online and offline adaptive radiotherapy, ensuring more personalized and effective care for patients.

A software product that is making its debut in China is also showcased at the expo, bringing the latest innovations in oncology software to the market. It integrates the best solutions to provide an elevated user experience, without compromising on the quality of treatment.

"As a leader in precision radiation medicine, we strive to increase accessibility to cancer care, build resilience, and continuously push the boundaries of innovation," Salford said.

The unveiling of these advanced solutions at the CIIE not only reflects Elekta's commitment to addressing the pressing needs of cancer patients but demonstrates its dedication to fostering collaborations that enhance the healthcare landscape in China.

"We are able to unleash the vitality of local innovation while serving the global market with the intelligent practice results in China. The results of these local innovations also have referential value to our global practice, which drives us to continue to innovate and bring more possibilities to cancer treatment," said Salford.

malinmiao@chinadaily.com.cn